Nataly Peres

Mrs. Nataly Peres

Universidade de São Paulo, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
GLGuilherme Lepski
Guilherme Lepski
PBPatricia C. Bergami-Santos
Patricia C. Bergami-Santos
MPMariana Pereira Pinho
Mariana Pereira Pinho
NCNadia E. Chauca-Torres
Nadia E. Chauca-Torres
GEGabriela Coeli Menezes Evangelista
Gabriela Coeli Menezes Evangelista
JBJosé Alexandre Marzagao Barbuto
José Alexandre Marzagao Barbuto
Immunotherapy for cancer treatment has gained increased attention in recent years. Recently, our group reported the case of a patient with glioblastoma who underwent vaccination based on dendritic cells and experienced a strong Th1 immune response together with near-complete tumor remission. Here we report the results of a phase I/II prospective, non-controlled clinical trial with 37 patients harboring glioblastoma or grade 4 astrocytomas. At the time of first recurrence after surgery, patients began receiving monthly intradermal injections of allogenic DC-autologous tumor cell hybridomas. Overall survival, quality of life, and immunological profiles were assessed prospectively. Compared with patients in the Genomic Data Commons data bank, overall survival for vaccinated patients with glioblastoma was 27.6 ± 2.4 months (vs. 16.3 ± 0.7, log-rank p < 0.001, hazard ratio 0.53, 95%CI 0.36–0.78, p < 0.01), and it was 59.5 ± 15.9 for vaccinated astrocytoma grade 4 patients (vs. 19.8 ± 2.5, log-rank p < 0.05, hazard ratio 0.18, 95%CI 0.05–0.62, p < 0.01). Furthermore, seven vaccinated patients (two IDH-1-mutated and five wild type) remain alive at the time of this report (overall survival 47.9 months, SD 21.1, range: 25.4–78.6 months since diagnosis; and 34.2 months since recurrence, range: 17.8 to 40.7, SD 21.3). We believe that the data reported here can foster the improvement of treatment protocols for high-grade gliomas based on cellular immunotherapy.

Verified
Journal Article
Open access
PDF file
MPMariana Pereira Pinho
Mariana Pereira Pinho
GLGuilherme Lepski
Guilherme Lepski
RRRoberta Rehder
Roberta Rehder
NCNadia E. Chauca-Torres
Nadia E. Chauca-Torres
GEGabriela Coeli Menezes Evangelista
Gabriela Coeli Menezes Evangelista
PBPatricia C. Bergami-Santos
Patricia C. Bergami-Santos
Immunotherapy has brought hope to the fight against glioblastoma, but its efficacy remains unclear. We present the case of CST, a 25-year-old female patient with a large right-hemisphere glioblastoma treated with a dendritic–tumor cell fusion vaccine. CST showed a near-complete tumor response, with a marked improvement in her functional status and simultaneous increases in tumor-specific CD8+ and CD4+ T cells. Two months before recurrence, the frequency of tumor-specific T cells decreased, while that of IL-17 and CD4+ T cells increased. CST passed away 15 months after enrollment. In this illustrative case, the tumor-specific CD4+ T-cell numbers and phenotype behaved as treatment efficacy biomarkers, highlighting the key role of the latter in glioblastoma immunotherapy.

17 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
GLGuilherme Lepski
Guilherme Lepski
Nataly PeresNataly Peres
Nataly Peres
PBPatrícia C. Bergami-Santos
Patrícia C. Bergami-Santos
MPMariana Pereira Pinho
Mariana Pereira Pinho
NTNadia E. Chauca Torres
Nadia E. Chauca Torres
JBJosé Alexandre Marzagao Barbuto
José Alexandre Marzagao Barbuto
Measuring quality of life (QoL) in patients with high-grade central nervous system (CNS) malignancies is crucial, as these patients often endure severe physical, cognitive, and emotional challenges that significantly impact their overall well-being. Understanding and improving QoL is essential for guiding treatment strategies that not only extend survival but also enhance daily functioning and patient satisfaction. This manuscript details a phase II trial investigating the effects of allogeneic dendritic cell (DC) vaccination in patients with recurrent glioblastoma (IDH-1 wild type) and grade 4 astrocytoma (IDH-1 mutated). Among the 37 participants enrolled, comprehensive quality of life data were analyzed for 20 patients. The results revealed a significant survival benefit, with median survival extended by 75% in the vaccinated glioblastoma group and by 200% in the astrocytoma group, compared with controls in the GDC database. Quality of life evaluations using validated instruments, including the EORTC QLQ-C30, FACT-Br, and MDASI, indicated marked improvements across multiple domains, such as general health, physical, emotional, cognitive, and social functioning, along with a reduction in symptom severity. These findings highlight the potential of DC vaccination to not only prolong survival but also enhance the overall quality of life for patients with high-grade CNS malignancies.